TRAVERE THERAPEUTICS, INC. Research and Development Expense (Excluding Acquired in Process Cost)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Research and Development Expense (Excluding Acquired in Process Cost) of $60.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $60.28M, a 22.12% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $57.09M, a 21.76% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $57.87M, a 6.76% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $51.89M, a 0.41% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2025 was $206.01M, a 5.28% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2024 was $217.50M, a 11.22% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2023 was $244.99M, a 7.77% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2022 was $227.33M, a 13.01% increase from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 3 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month as first filed | Research and Development Expense (Excluding Acquired in Process Cost) 12 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $60.28M 10-Q · filed 2026-08-04 | $117.38M 10-Q · filed 2026-08-04 | $175.25M derived: sum of 3 quarters · filed 2026-08-04 | $227.14M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $57.09M 10-Q · filed 2026-05-04 | $114.96M derived: sum of 2 quarters · filed 2026-05-04 | $166.85M derived: sum of 3 quarters · filed 2026-05-04 | $216.22M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $57.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $109.76M derived: sum of 2 quarters · filed 2026-02-19 | $159.12M derived: sum of 3 quarters · filed 2026-08-04 | $206.01M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $51.89M 10-Q · filed 2025-10-30 | $101.25M derived: sum of 2 quarters · filed 2026-08-04 | $148.14M 10-Q · filed 2025-10-30 | $210.21M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $49.36M 10-Q · filed 2026-08-04 | $96.25M 10-Q · filed 2026-08-04 | $158.32M derived: sum of 3 quarters · filed 2026-08-04 | $210.00M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $46.89M 10-Q · filed 2026-05-04 | $108.96M derived: sum of 2 quarters · filed 2026-05-04 | $160.63M derived: sum of 3 quarters · filed 2026-05-04 | $214.97M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $62.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $113.75M derived: sum of 2 quarters · filed 2026-02-19 | $168.08M derived: sum of 3 quarters · filed 2026-02-19 | $217.50M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $51.68M 10-Q · filed 2025-10-30 | $106.01M derived: sum of 2 quarters · filed 2025-10-30 | $155.43M 10-Q · filed 2025-10-30 | $215.18M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | $54.33M 10-Q · filed 2025-08-06 | $103.75M 10-Q · filed 2025-08-06 | $163.50M derived: sum of 3 quarters · filed 2026-02-19 | $224.09M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $49.42M 10-Q · filed 2025-05-01 | $109.17M derived: sum of 2 quarters · filed 2026-02-19 | $169.76M derived: sum of 3 quarters · filed 2026-02-19 | $236.25M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $59.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $120.34M derived: sum of 2 quarters · filed 2026-02-19 | $186.83M derived: sum of 3 quarters · filed 2026-02-19 | $244.99M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $60.59M 10-Q · filed 2024-10-31 | $127.08M derived: sum of 2 quarters · filed 2024-10-31 | $185.24M 10-Q · filed 2024-10-31 | $243.33M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $66.49M 10-Q · filed 2024-08-01 | $69.41M 10-Q · filed 2023-08-03 | $124.65M 10-Q · filed 2024-08-01 | $129.32M 10-Q · filed 2023-08-03 | $182.74M derived: sum of 3 quarters · filed 2025-02-21 | $239.89M derived: sum of 4 quarters · filed 2025-02-21 | ||
| 2023-03-31 | $58.16M 10-Q · filed 2024-05-06 | $59.91M 10-Q · filed 2023-05-04 | $116.25M derived: sum of 2 quarters · filed 2025-02-21 | $173.39M derived: sum of 3 quarters · filed 2025-02-21 | $233.07M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2022-12-31 | $58.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $115.23M derived: sum of 2 quarters · filed 2025-02-21 | $174.91M derived: sum of 3 quarters · filed 2025-02-21 | $227.33M 10-K · filed 2025-02-21 | $235.78M 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $57.15M 10-Q · filed 2023-11-07 | $59.26M 10-Q · filed 2022-10-27 | $116.83M derived: sum of 2 quarters · filed 2023-11-07 | $169.25M 10-Q · filed 2023-11-07 | $175.55M 10-Q · filed 2022-10-27 | $226.44M derived: sum of 4 quarters · filed 2024-02-20 | ||
| 2022-06-30 | $59.68M 10-Q · filed 2023-08-03 | $116.29M 10-Q · filed 2023-08-03 | $169.29M derived: sum of 3 quarters · filed 2024-02-20 | $217.70M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $56.61M 10-Q · filed 2023-05-04 | $109.61M derived: sum of 2 quarters · filed 2024-02-20 | $158.02M derived: sum of 3 quarters · filed 2024-02-20 | $209.82M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $101.41M derived: sum of 2 quarters · filed 2024-02-20 | $153.21M derived: sum of 3 quarters · filed 2024-02-20 | $201.16M 10-K · filed 2024-02-20 | $210.33M 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $48.41M 10-Q · filed 2022-10-27 | $100.21M derived: sum of 2 quarters · filed 2022-10-27 | $148.16M 10-Q · filed 2022-10-27 | |||||
| 2021-06-30 | $51.81M 10-Q · filed 2022-08-04 | $99.75M 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | $47.95M 10-Q · filed 2022-05-05 | |||||||
| 2020-12-31 | $131.77M 10-K · filed 2023-02-23 | |||||||
| 2019-12-31 | $140.96M 10-K · filed 2022-02-24 | |||||||
| 2018-12-31 | $123.76M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |